Bispecific Antibody Hematology Deal Benchmarks
Market Analysis
Bispecific antibodies have emerged as a major competitive force in hematologic oncology, challenging CAR-T cell therapy with off-the-shelf convenience and lower manufacturing complexity. Phase 2 bispecific hematology deals carry a median total deal value of $3.6B, with upfront payments of $717M. Approved agents like glofitamab, epcoritamab, and teclistamab have validated the bispecific approach across lymphoma and myeloma.
Deal structures for hematology bispecifics reflect the rapid clinical development timelines and accelerated approval pathways. Development milestones average $601M, regulatory milestones contribute $716M, and commercial milestones reach $1.5B. The overall 20/80 upfront/milestone split reflects moderate clinical risk at Phase 2.
Royalty rates for hematology bispecific deals range from 9% to 16.9%, with escalation to 20.9% on peak sales. Key differentiation factors include subcutaneous versus intravenous formulation, step-up dosing requirements, cytokine release syndrome profile, and activity in CAR-T-refractory patients. Fixed-duration therapy bispecifics command premium terms over continuous treatment approaches.
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Customize these benchmarks for your asset
Adjust phase, modality, competitive position, and 10+ other parameters.
Frequently Asked Questions
What are typical deal terms for hematology bispecific antibodies?
How do bispecific deals compare to CAR-T deals in hematology?
Which bispecific targets are most valued in hematology?
What drives premium valuations for hematology bispecifics?
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Ready to Calculate Your Deal Terms?
Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.
Start CalculatingNeed the full deal landscape?
The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.